Evidence map›Paper›PMID 37824763›Full record

ArticleBlood cancer discovery2023

Potent Personalized Venetoclax Partners for Acute Myeloid Leukemia Identified by Ex Vivo Drug Screening.

Pamela S Becker

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Pandora's Box of AML: HowBiomedicines · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Pamela S BeckerDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.ORCID 0000-0001-6235-9463

Funding

Tumor mutation signaturesP01CA077852 · NCI · UNIVERSITY OF WASHINGTON · PI SIDOROVA, JULIA · 1999 to 2019
$26.0M
Development of Innovative Resources to Advance MDS ResearchRC2DK127989 · NIDDK · FRED HUTCHINSON CANCER CENTER · PI Marie Bleakley, Sergei Doulatov · 2023 to 2026
$6.2M
NCI NIH HHS P01 CA077852NIDDK NIH HHS RC2 DK127989
6 · The paper itself

Abstract

summaryHigh-throughput screens (HTS) have been utilized to assess the efficacy of single drugs against patient tumor samples with the purpose of optimizing precision therapy, but testing the synergy of drug combinations can identify the ideal second drug to add. With novel sophisticated HTS, effective venetoclax combinations can be revealed that provide the cell state, phenotype, and molecular features of the susceptible and resistant cell populations. See related article by Eide, Kurtz et al., p. 452 (14) .

Indexed as

Leukemia, Myeloid, AcuteBridged Bicyclo Compounds, HeterocyclicDrug Evaluation, PreclinicalHumansSulfonamidesBridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclax

Identifiers

PMID37824763
PMCPMC10625347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.